XEMBIFY normal immunoglobulin 2 g/10 mL (20%) solution for subcutaneous injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

xembify normal immunoglobulin 2 g/10 ml (20%) solution for subcutaneous injection vial

grifols australia pty ltd - human immunoglobulin g, quantity: 1800 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Hipraject Subcutaneous Philippines - English - FDA (Food And Drug Administration)

hipraject subcutaneous

hipra philippines, inc.; distributor: hipra philippines, inc. - subcutaneous vaccination device (vet.) - subcutaneous - not applicable

Neo-Mercazole New Zealand - English - Medsafe (Medicines Safety Authority)

neo-mercazole

aft pharmaceuticals ltd - carbimazole 5mg;  ; carbimazole 5mg - tablet - 5 mg - active: carbimazole 5mg   excipient: acacia gelatin iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propyl hydroxybenzoate purified talc sucrose active: carbimazole 5mg excipient: acacia gelatin iron oxide red lactose monohydrate magnesium stearate maize starch purified talc sucrose - primary thyrotoxicosis, even in pregnancy. secondary thyrotoxicosis - toxic nodular goitre. however, neo-mercazole really has three principal applications in the therapy of hyperthyroidism: 1. definitive therapy - induction of a permanent remission. 2. preparation for thyroidectomy. 3. before and after radio-active iodine treatment.

UTIBRON NEOHALER- indacaterol and glycopyrrolate capsule United States - English - NLM (National Library of Medicine)

utibron neohaler- indacaterol and glycopyrrolate capsule

novartis pharmaceuticals corporation - indacaterol maleate (unii: 2jec1itx7r) (indacaterol - unii:8or09251mq), glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - indacaterol 27.5 ug - utibrontm neohaler® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use: utibron neohaler is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see warnings and precautions (5.1, 5.2)] . all labas are contraindicated in patients with asthma without use of a long-term asthma control medication [see warnings and precautions (5.1)] . utibron neohaler is not indicated for the treatment of asthma. utibron neohaler is contraindicated in patients who have demonstrated hypersensitivity to indacaterol, glycopyrrolate, or to any of the ingredients [see warnings and precautions (5.5)] . teratogenic effects: pregnancy category c there are no adequate and well-controlled studies with utibron neohaler or its individual components, indacaterol and glycopyrrolate, in pregnant women

TAVNEOS Israel - English - Ministry of Health

tavneos

cts ltd - avacopan - hard capsule - avacopan 10 mg - avacopan - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

TRANSIDERM-NITRO 25 glyceryl trinitrate 25 mg transdermal drug delivery system sachet Australia - English - Department of Health (Therapeutic Goods Administration)

transiderm-nitro 25 glyceryl trinitrate 25 mg transdermal drug delivery system sachet

sandoz pty ltd - glyceryl trinitrate, quantity: 25 mg - drug delivery system, transdermal - excipient ingredients: lactose monohydrate; dimeticone; colloidal anhydrous silica; polyethylene terephthalate; aluminium; ethylene/vinyl acetate copolymer; polyvinyl chloride; trichlorotrifluoroethane; simethicone - indicated for the prevention of chronic stable angina pectoris due to coronary artery disease.

Betnovate Scalp Application 0.1% w/v Cutaneous Solution Ireland - English - HPRA (Health Products Regulatory Authority)

betnovate scalp application 0.1% w/v cutaneous solution

glaxosmithkline (ireland) limited - betamethasone - cutaneous solution - 0.1 percent weight/volume - corticosteroids, potent (group iii); betamethasone

Bettamousse 1mg/g (0.1%) cutaneous foam Ireland - English - HPRA (Health Products Regulatory Authority)

bettamousse 1mg/g (0.1%) cutaneous foam

rph pharmaceuticals ab - betamethasone valerate - cutaneous foam - 1 (0.1%) milligram(s)/gram - corticosteroids, potent (group iii); betamethasone

Dermovate Scalp Application 0.05% w/v Cutaneous Solution Ireland - English - HPRA (Health Products Regulatory Authority)

dermovate scalp application 0.05% w/v cutaneous solution

glaxosmithkline (ireland) limited - clobetasol propionate - cutaneous solution - 0.05 percent weight/volume - corticosteroids, very potent (group iv); clobetasol

DIFENE SPRAY GEL 4 %w/w Cutaneous Spray Solution Ireland - English - HPRA (Health Products Regulatory Authority)

difene spray gel 4 %w/w cutaneous spray solution

astellas pharma co. ltd - diclofenac sodium - cutaneous spray solution - 4 %w/w - antiinflammatory preparations, non-steroids for topical use